key: cord-0959626-bq0hm89l
authors: Almasi, Faezeh; Mohammadipanah, Fatemeh
title: Hypothetical targets and plausible drugs of coronavirus infection caused by SARS‐CoV‐2
date: 2020-08-03
journal: Transbound Emerg Dis
DOI: 10.1111/tbed.13734
sha: 0d3434744c6744544238e39e0a08a2dcac176761
doc_id: 959626
cord_uid: bq0hm89l

The world is confronting a dire situation due to the recent pandemic of the novel coronavirus disease (SARS‐CoV‐2) with the mortality rate passed over 470,000. Attaining efficient drugs evolve in parallel to the understanding of the SARS‐CoV‐2 pathogenesis. The current drugs in the pipeline and some plausible drugs are overviewed in this paper. Although different types of anti‐viral targets are applicable for SARS‐CoV‐2 drug screenings, the more promising targets can be considered as 3C‐like main protease (3Cl protease) and RNA polymerase. The remdesivir could be considered the closest bifunctional drug to the provisional clinical administration for SARS‐CoV‐2. The known molecular targets of the SARS‐CoV‐2 include fourteen targets, while four molecules of angiotensin‐converting enzyme 2 (ACE2), cathepsin L, 3Cl protease and RNA‐dependent RNA polymerase (RdRp) are suggested as more promising potential targets. Accordingly, dual‐acting drugs as an encouraging solution in drug discovery are suggested. Emphasizing the potential route of SARS‐CoV‐2 infection and virus entry‐related factors like integrins, cathepsin and ACE2 seems valuable. The potential molecular targets of each phase of the SARS‐CoV‐2 life cycle are discussed and highlighted in this paper. Much progress in understanding the SARS‐CoV‐2 and molecular details of its life cycle followed by the identification of new therapeutic targets are needed to lead us to an efficient approach in anti‐SARS‐CoV‐2 drug discovery.

conferring crown-like shape on the outer surface. The attachment of SARS-CoV-2 via the interplay of its S protein with the receptor on the host cell and angiotensin-converting enzyme is the primary stage in its life cycle which is followed by proteolytic cleavage of S protein into 2 subunits namely S1 and S2 and virus enters the cytosol (S1 mediates attachment and S2 mediates virus fusion). N protein is structurally bound to the genome of the virus and is necessary for viral RNA transcription and replication. The other critical structural protein is M protein that is involved in shaping the viral envelope. By binding to the other proteins, this protein helps to stabilize N proteins and promotes the ending of viral assembly. Finally, the E protein plays a role in the production and maturation of SARS-CoV-2.

After the viral entry, the second step is the expression of replicase proteins. Following replication and RNA synthesis (third step) and assembly (last step), virions are escaped from the cell by the aid of exocytosis (Figure 2 ) (Fehr & Perlman, 2015) .

There are three lines of drug discovery approach to develop the novel drug for SARS-CoV-2. These three approaches lead to the potential treatment options including the drug repurposing, screening molecular databases using drug design tools and screening the compound libraries in anti-viral assays. By the time demanded to randomly screen the natural or chemical compound libraries, the third option is not compatible with the rapid rate of SARS-CoV-2 transmission in the community. Therefore, drug repurposing and computational docking analysis are the two main current approaches to find potential agents for SARS-CoV-2 therapy.

The efficiency of seven anti-viral drugs (ribavirin, nafamostat, nitazoxanide, penciclovir, chloroquine (CQ) remdesivir and favipiravir) on only a single clinical type of SARS-CoV-2 is so far evaluated in the wet laboratory. These drugs have previously exhibited an acceptable anti-viral activity on various types of RNA viruses such as SARS-CoV, MERS-CoV and Ebola virus (EBOV) (García-Serradilla, Risco, & Pacheco, 2019) . The investigated potential anti-SARS-CoV-2 described in recent repurposing programmes is presented in Table 1 . The cell culture investigations showed that the compounds chloroquine (CQ) and remdesivir (RDV) effectively inhibited the infection by SARS-CoV-2 with a high selectivity index at low enough micromolar concentration . Remdesivir (RDV, is an adenosine analogue that has completed the clinical trial phase III for the purpose of viral infection control caused by the Ebola virus. The remdesivir is entered to the phase III clinical trials in Asian countries to assess the use of antiviral drug candidate for the potential treatment of SARS-CoV-2 by Gilead Sciences. All reported potential drug candidates in clinical trials and their status are presented in Table 2 . Moreover, multiple parallel attempts are in progress to develop SARS-CoV-2 vaccine.

At the time of writing the article, 128 vaccine candidates are in preclinical phases and 16 candidates are in clinical phases (Table 3) .

Despite the possibility of surface alteration of RNA viruses, blocking the cell surface viral receptor, thereby inhibiting the virus entry, can be a proper option in designing the approach of drug discovery.

The schematic diagram (original in this paper) of the SARS-CoV-2 surface proteins Binding of the viral spike (S) glycoproteins to cellular receptor ACE2 and priming the S protein by transmembrane serine protease 2 (TMPRSS2) are both the essential factors for cell entry of coronaviruses. TMPRSS2 mediates the entry by two distinct mechanisms. One mechanism is the cleavage and activation of the spike glycoproteins of coronaviruses (like HCoV-229E and HCoV-EMC) which facilitates the virus-cell membrane entry. Conformational flexibility of S protein which is needed for fusion will be created by proteolytic cleavages (Bosch, van der Zee, de Haan, & Rottier, 2003) catalysed by TMPRSS2 as the most relevant cellular proteases in this process. Another mechanism is the proteolytic cleavage of angiotensin-converting enzyme 2 (ACE2) by TMPRSS2, which might activate the coronavirus spike glycoprotein. Proteolytic cleavages of S protein happen only after ACE2 cleavage results in SARS-CoV-2-cell membrane fusion and cathepsin L-independent cell entry. SARS-CoV-2 RNA is then released into the cytoplasm, and viral replication is efficiently processed (Table 4 ).

A type I membrane zinc metalloprotease named angiotensin-converting enzyme 2 (ACE2) is mainly expressed in arterial cells and lung alveolar F I G U R E 2 Cell cycle of SARS-CoV-2 in the host cells. The virus goes into the target cells via direct membrane fusion (a) or a clathrinmediated endosomal pathway (b). Binding of the surface unit of the S protein (S1) to angiotensin-converting enzyme 2 (ACE2) facilitates the viral attachment. Viral fusion is primed by TMPRSS2, and the active spike protein of SARS-CoV-2 acquires an RGD motif (in itsS1 domain) known to bind integrins. The attachment to integrin may play an auxiliary role in ACE2 binding, like simplifying endocytosis by signalling through the integrin. RGD is not found in other coronaviruses. The viral RNA is unveiled by the effect of endosomal cathepsins at low pH. Following, the replicase gene of the viral genome is translated into large polyproteins which are cleaved by the proteases to yield 16 nonstructural proteins (nsps). In consequence of replication, transcription and translation, assembly of nucleocapsids with RNA and N proteins is occurred in the cytoplasm, followed by budding into golgi intermediate compartment. Then, the enveloped virus is exocytosed. Plausible drugs inhibiting each step of the cycle are indicated in light blue boxes TA B L E 1 Potential repurposing candidates with effectiveness on SARS-CoV-2 

epithelial cells. ACE2 hydrolyses the angiotensin I to produce angiotensin (1-9) (Donoghue et al., 2000) . The enzyme is known for its implication as the virus receptor of SARS-CoV (Kuba et al., 2005) which was proved as the cellular receptor of SARS-CoV-2 by Zhou et al .

Blocking the entrance of SARS-CoV-2 through the intervention of ACE2 seems to be a possible target for anti-viral drug discovery.

Recently, Sigrist et al suggested that SARS-CoV-2 may also bind to integrins on the host cells, through a conserved motif (RGD) containing

Arg-Gly-Asp in receptor-binding domain of S protein that is absent in can be considered a prolific target for anti-viral drug discovery.

The growth factor receptors of receptor tyrosine kinases (RTKs) are autophosphorylated after ligand binding being involved in mediating cell-to-cell communication and controlling a vast range of complicated biological processes like cell growth, motility and differentiation (Lemmon & Schlessinger, 2010) . The sequel of ligand binding is conformational changes of RTKs enabling its autophosphorylation and therefore activation of a wide variety of downstream cellular signalling pathways. RTKs also play a critical role in signalling pathways, such as the Ras/mitogen-activated protein kinase (MAPK), PI3K/Akt and JAK/STAT pathways. The particular RTK blockers, known as AG879

and tyrphostin A9 (A9), are also reported as strong anti-viral activity against the influenza A virus (Kumar, Liang, Parslow, & Liang, 2011) .

It was shown that the approved blockers can impair the infection of major HCV variants in in vitro and in vivo models (Jilg & Chung, 2012) .

The tyrosine kinase inhibitor such as genistein can also block the replication of arenavirus, herpes simplex virus type 1 (HSV-1) and HIV-1 

The trimeric S glycoprotein responsible for the coronaviruses crown-like appearance mediates attachment to the host receptor (Ou et al., 2020) . Despite the over 72% spike protein sequence similarity with SARS-CoV, a peculiar furin-like cleavage site at the S1/ S2 position in the S protein sequence of the SARS-CoV-2 was identified, missing in the other SARS-like CoVs (Coutard et al., 2020) . 

The cessation of the capsid disintegration by viral or host enzymes/ proteins is a drug target explored against the influenza virus, rhinoviruses, hepatitis A, poliovirus and enteroviruses (Yamauchi & Greber, 2016) . In accordance with this approach, rimantadine inhib- 

PLprotease or nsp3 releases proteins involved in both replication of coronavirus and infection processes. In addition to the LXGG motif found in-between nsp1/2, nsp 2/3 and nsp 3/4, it has two other proteolytic activities, removal of ubiquitin (Ub) and ubiquitin-like protein ISG15 (interferon induced gene 15) from cellular proteins. (Ratia et al., 2008) . PLpro inhibitors of MERS-CoV (Kilianski, Mielech, Deng, & Baker, 2013) , HEV (Saraswat, Chaudhary, & Sehgal, 2020) , etc have also been reported. Another

PLpro inhibitor named disulfiram has been identified to block the function of this enzyme in MERS and SARS in in vitro, but clinical approval of its effectiveness is lacking (Li & De Clercq, 2020) . The inhibition of PLpro can be assumed as a promising target in coronavirus drug discovery.

3CLprotease (also called the major protease (Mpro) or nsp5 di- expecting to exhibit excellent anti-viral activity against SARS-CoV-2 (Li & De Clercq, 2020; Zhang, Lin, et al., 2020) .

Genome multiplication is critical in the life cycle of the virus and can be an attractive target for the intervention in the infection progress.

RNA-dependent RNA polymerase (RdRp) (nsp12) or RNA replicase is the most principal protein in the coronavirus replication/transcription complex . 

Helicase (nsp13) press the helicase of SARS-CoV (Yu et al., 2012) . The potent inhibition of SARS coronavirus replication and the helicase activity with EC50 of less than 10 μM is also reported by the Adamantane-derived

Bananins (Tanner et al., 2005) .

The 18-kDa cytosolic cyclophilin A is a necessary cellular molecule needed for replication of RNA viruses including HIV (Luban, Bossolt, Franke, Kalpana, & Goff, 1993) , HCV (Watashi et al., 2005) , influenza 

Nucleoside analogues (dNTPs or rNTPs without 3′-OH group resulting in chain termination) are extensively applied for the hepatitis C virus (HCV), hepatitis B virus (HBV), HIV-1 and HSV therapy.

Compared to the other RNA viruses, the proofreading activity of RdRp by the capability of 3′ to 5′ exoribonuclease (nsp14) leads up to 20-fold enhancement in the accuracy of replication. Thus, the enzyme of coronavirus is rather resistant to many nucleoside analogues including favipiravir (guanine analogue), ribavirin (guanosine analogue) and 5-fluorouracil (pyrimidine analogue) (Harrison, 2020) .

Remdesivir, (adenosine analogue) as a potent phosphoramidate prodrug, is effective against filoviruses, pneumoviruses and paramyxoviruses with two suggested mechanisms of action (Lo et al., 2017) . One is being as nucleoside analogue and the second is acting on viral RdRp.

analogues suggesting that compound 2 with EC50 < 10 μM was promising against HCoV-NL63 (Peters et al., 2015) . The combinations of nucleotide analogues can mitigate the resistance mediated by mutations in the viral RdRp, perhaps by additive or synergistic interactions effect (Pruijssers & Denison, 2019) . Despite the proofreading activity, identifying nucleoside analogue inhibitors hold promise for the treatment of SARS-CoV-2. (Qin, Zhao, Cao, & Qi, 2007) .

The inhibition of viral assemble is investigated for different types of viruses including moloney murine leukaemia virus (Mo-MLV) (McNally, Wahlin, & Canto-Soler, 2010) , classical swine fever virus (CSFV) (Zhou, Liu, & Chen, 2008) , HIV-2 (Wu et al., 1995) , HIV-1 (Li et al., 2009) , dengue virus type 2 (DENV2) (Qin et al., 2005) , HBV (Seo et al., 2019) and influenza A (Liu et al., 2014) . However, no approved drug candidate or in clinical trial disparting the SARS-CoV-2 assembly is reported so far. Bone marrow matrix antigen 2 (BST-2), also known as tetherin or CD 317, was found as the factor causing a defect in virion release of HIV-1 mutants without the vpu accessory gene (Van Damme et al., 2008) .

One of the coronavirus virulence factors is ORF7a that inhibits the bone marrow matrix antigen 2 (BST-2) (Taylor et al., 2015) related to its escape from the innate immune system by host mRNA degradation and interferon production inhibition. BST-2 is constitutively expressed in plasma cells, mature B cells and type I interferon-producing cells that can hinder the liberation of biosynthesized coronavirus from hosts. The evidence implied that ORF7a can be speculated as a potential target for anti-viral drug discovery of SARS-CoV-2.

In the preceding 20 years, two novel coronaviruses have been The potential molecular targets in anti-SARS-CoV-2 drug discovery are surveyed in this paper that can be employed in HTS programmes for systematic drug discovery for SARS-CoV-2 infection. While full-length S proteins of SARS-CoV-2 and SARS-CoV have up to 76% similarities in amino acid sequences, the N-terminal domain that binds to the receptor shows only 53.5% of homology reflecting its potential to bind different sugars. Therefore, emphasizing on other virus entry-related factors like cathepsin seems valuable for SARS-CoV-2 drug discovery. In fact, host proteases cathepsin L and TMPRSS2 prepare the SARS-CoV-2 S protein for cell entry (Walls et al., 2020) . Considering the results of repurposing strategies and clinical tests until now, remdesivir seems a promising dual-acting drug (inhibiting viral RNA polymerases and 3C-like main protease). Studies conducted so far suggest the drug might cause some minor side effects including nausea, liver damage and cardiopulmonary failure.

Beyond the ongoing studies of remdesivir, now researchers are hoping to explore whether the remdesivir can be combined with other anti-viral drugs for making a more effective SARS-CoV-2 combating cocktail. Six clinical trials are currently underway to specify testing remdesivir with other medicines, according to Informa Pharma

Intelligence. Nevertheless, HIV protease inhibitors (ritonavir/lopinavir/ASC09), favipiravir and chloroquine need further investigations.

As we proceed with the current molecular docking studies and presuming the effectiveness of the existing anti-viral compounds, the de novo drug discovery will join to evaluate the modulation of the new molecular targets of SARS-CoV-2 in bioassay platforms which were discussed above. To accelerate the long, costly and rigorous process of drug discovery, high-throughput methods and high-content screening methods can be employed. However, by the immediate global need for drugs to control the SARS-CoV-2 infection drug search is currently pursued by the repurposing approach. Accordingly, the critical viral life cycle steps like entry, genome and protein synthesis reflect the multiple drug target groups not limited to 3cl pro and

RdRp that can be addressed by the conventional de novo strategy of drug discovery. Assembly and release inhibitors are less considered steps in SARS-CoV-2 life cycle for its drug discovery. While most of the drug cases for SARS-CoV-2 are registered for the control purpose rather than prophylaxis; S protein, integrins and ACE2 targets are of value for drug repurposing or discovery programmes to hinder the viral entry and fusion process. Considering the fact that the primary goal of all viruses is to deliver and replicate their genome to the competent host cells, blocking angiotensin-converting enzyme 2 (ACE2), cathepsin L, 3Cl protease and RdRp are suggested to be promising targets for anti-SARS-CoV-2 drug discovery.

This paper was not funded by any organization.

No conflict of interest is declared on the data collected and interpreted in this paper.

The authors declare that no ethical was needed for the current nonexperimental paper.

The paper is a review and does not have original experimental data to make them available.

Fatemeh Mohammadipanah https://orcid. org/0000-0003-0286-5342

Mechanism of nucleic acid unwinding by SARS-CoV helicase

Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase

Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses

Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: An in silico strategy unveils a hope against CORONA

Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease

The possible of immunotherapy for COVID-19: A systematic review

Amantadine as a drug to mitigate the effects of COVID-19

Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs

Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay

The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

Features, evaluation and treatment coronavirus (COVID-19)

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus

Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies

Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins

The spike glycoprotein of the new coronavirus SARS-COV-2 contains a furin-like cleavage site absent in CoV of the same clade

Thalidomide against coronavirus disease 2019 (COVID-19): A medicine with a thousand faces

Approved antiviral drugs over the past 50 years

Alisporivir inhibits MERS-and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model

Cyclophilins and cyclophilin inhibitors in nidovirus replication

Cyclosporin A inhibits the replication of diverse coronaviruses

Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Anti-SARS and anti-HCV drugs repurposing against the papain-like protease of the newly emerged coronavirus (SARS-COV-2). Research Square

Coronaviruses: An overview of their replication and pathogenesis in Coronaviruses

Antiviral compounds and methods

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Drug repurposing for new, efficient, broad spectrum antivirals

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Coronavirus puts drug repurposing on the fast track

SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro

Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19

Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication

Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025

Cell signaling by receptor tyrosine kinases

Integrinbased therapeutics: Biological basis, clinical use and new drugs

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid

Human Coronaviruses: General Features. Reference Module in Biomedical Sciences

Cofilin-1 is involved in regulation of actin reorganization during influenza A virus assembly and budding

Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines

Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)

Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B

Maoto, a traditional Japanese herbal medicine, inhibits uncoating of influenza virus

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Endogenous expression of ASLV viral proteins in specific pathogen free chicken embryos: Relevance for the developmental biology research field

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies

Potentially highly potent drugs for 2019-nCoV

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity

The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors

Nucleoside analogues for the treatment of coronavirus infections. Current Opinion in Virology

Therapeutic effects of dengue 2 virus capsid protein and staphylococcal nuclease fusion protein on dengue-infected cell cultures

siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA

A noncovalent class of papain-like protease/ deubiquitinase inhibitors blocks SARS virus replication

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana De Salud Pública

Hepatitis E virus cysteine protease has papain like properties validated by in silico modeling and cell-free inhibition assays

Coronavirus envelope protein: Current knowledge

α5 β1-Integrin controls ebolavirus entry by regulating endosomal cathepsins

Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly

silico studies on therapeutic agents for COVID-19: Drug repurposing approach

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase

A potential role for integrins in host cell entry by SARS-CoV-2

Repurposing therapeutics for covid-19: Supercomputer-based docking to the sars-cov-2 viral spike protein and viral spike protein-human ace2 interface

COVID-19: Combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases

Lopinavir-ritonavir in severe COVID-19

Virtual Screening Based Prediction of Potential Drugs for COVID-19. Preprints

The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus

Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference

Mechanism of inhibition of Ebola Virus RNA-dependent RNA polymerase by remdesivir

The COVID-19 vaccine development landscape

Of chloroquine and COVID-19

Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells

The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein

Genistein treatment of cells inhibits arenavirus infection

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (SARS-COV-2) in vitro

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

SARS coronavirus E protein forms cation-selective ion channels

Severe Acute Respiratory Syndrome (SARS) in Taiwan, China

Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx

Inhibition of SARS-CoV-2 infection (previously 2019-nCoVSARS-COV-2) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation

Principles of virus uncoating: Cues and the snooker ball

Discovery of potential drugs for COVID-19 based on the connectivity map

α6 integrin is the main receptor of human papillomavirus type 16 VLP

Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13

The epidemiology, diagnosis and treatment of COVID-19

Teicoplanin potently blocks the cell entry of 2019-nCoV

α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment

Potential interventions for novel coronavirus in China: A systemic review

Establishment and identification of classical swine fever virus (CSFV) capsid targeted nuclease expression system

A pneumonia outbreak associated with a new coronavirus of probable bat origin

How to cite this article: Almasi F, Mohammadipanah F. Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2